Serving Clients Nationwide From Our Texas Offices in Corpus Christi, San Antonio & Austin
The U.S. Food and Drug Administration (FDA) announced the first voluntary recall of certain products containing valsartan on July 13, 2018, due to the discovery of an impurity in the drugs. The impurity, N-nitrosodimethylamine, or NDMA, is a probable human carcinogen, which means that it poses a potential cancer risk to those taking the drug.
Contact Us for a Free Case Review
Impurities found in certain hypertension drugs linked to potential cancer risk
Not all drugs containing valsartan are under recall. The recalled hypertension drugs, thus far, contain valsartan medicine manufactured by Zhejiang Huahai Pharmaceuticals (Linhai, China) or Hetero Labs Limited (India). The FDA investigation is ongoing and the list of recalled valsartan-containing products is continuously updated. To see a full list of recalled valsartan products, see the chart below on this page or view the full list on the FDA’s website.
Did You Suffer Liver Damage After Using Valsartan? Call Thomas J. Henry
If you have been diagnosed with any of the following after taking a recalled valsartan drug, contact Thomas J. Henry immediately to discuss your case with an attorney:
- Liver damage, including liver fibrosis and scarring of the liver
- Tumors of the liver
- Liver cancer
Our pharmaceutical drug attorneys will provide you with a free legal consultation. Fill out the contact form on this page or call Thomas J. Henry to speak with a lawyer today.